Catheter-based thrombectomy systems are increasingly being used to remove blood clots from vessels inside the body, often as an adjunct therapy to systemic pharmaceutical thrombolytics.  These systems are used in veins, as in the case of deep vein thrombosis (DVT), and in arteries, in the case of pulmonary embolism (PE), ST-elevated myocardial infarction (STEMI) and ischemic stroke.  The systems can also quickly clear dialysis arteriovenous grafts, which are prone to thrombus formation. 



The interventional cardiology market includes, but is not limited to, drug-eluting stents, bare-metal stents, percutaneous transluminal coronary angioplasty (PTCA) and cutting balloon catheters. Although this market is growing overall, some segments are experiencing low negative growth and even dropping in value. Currently there are a few top competitors that hope to gain market share by bringing bioabsorbable stents into the U.S market.


My job as editor of DAIC is to help readers keep tabs on the latest in cardiovascular technology and trends. With collaboration from my Editorial Advisory Board, we developed a 2013 editorial calendar based on several predictions on what will be the key game-changing technologies.  These were determined from observations at numerous cardiology meetings we attended and from needs or trends members of the board have seen in their own practices. Here are our top predictions:


My job as editor of DAIC is to help readers keep tabs on the latest in cardiovascular technology and trends. With collaboration from my Editorial Advisory Board, we developed a 2013 editorial calendar based on several predictions on what will be the key game-changing technologies.  These were determined from observations at numerous cardiology meetings we attended and from needs or trends members of the board have seen in their own practices. Here are our top predictions:

Biotronik recently launched its 3Flow Aspiration Catheter in Europe. The catheter is specifically designed to facilitate quick and accurate thrombus aspiration, complementing Biotronik’s already broad coronary vascular intervention (CVI) portfolio.

Few issues are more important to the American College of Cardiology (ACC) and the American Heart Association (AHA) than translating the best available scientific evidence into clinical practice guidelines that can be used by healthcare professionals to improve patient outcomes and the quality of cardiovascular care. This is evidenced by the 17 clinical practice guideline topics — and many more updates — the organizations have jointly developed and published since the early 1980s through a highly robust process and methodology that continues to evolve.


Direct Flow Medical Inc. has received CE mark for its distinctive transcatheter aortic heart valve with metal-free frame and low-profile transfemoral delivery system.


Subscribe Now